AHRI Data Repository
Data Catalog
  • Home
  • Microdata Catalog
  • Citations
  • Login
    Login
    Home / Central Data Catalog / DREAMS / AHRI.LAPIS.ESOURCE.CLINICAL.MANAGEMENT.2025.V1
DREAMS

cRCT of Long-acting PrEP Integrated with Community-based Sexual Health (LAPIS) – Clinical Management

South Africa, 2024 - 2026
Get Microdata
Reference ID
AHRI.LAPIS.ESource.Clinical.Management.2025.v1
Producer(s)
Prof. Maryam Shahmanesh, Dr. Limakatso Lebina
Collections
Multilevel HIV Prevention
Metadata
Documentation in PDF DDI/XML JSON
Created on
Feb 06, 2025
Last modified
Feb 06, 2025
Page views
9847
Downloads
13
  • Study Description
  • Data Dictionary
  • Downloads
  • Get Microdata
  • Identification
  • Version
  • Scope
  • Coverage
  • Producers and sponsors
  • Sampling
  • Data collection
  • Data processing
  • Data Access
  • Metadata production
  • Identification

    Survey ID number

    AHRI.LAPIS.ESource.Clinical.Management.2025.v1

    Title

    cRCT of Long-acting PrEP Integrated with Community-based Sexual Health (LAPIS) – Clinical Management

    Country
    Name Country code
    South Africa ZA
    Abstract

    Long-acting HIV Pre-Exposure Prophylaxis integrated with community-based sexual and reproductive health in South Africa (LAPIS): A hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation. Offering a choice of long-acting PrEP, such as the 2 monthly injectable cabotegravir (CAB LA) within the community-based delivery of SRH integrated with oral PrEP, post-exposure prophylaxis, and dapivirine vaginal ring will overcome the uptake, adherence, and retention challenges of oral PrEP and lead to a population-level effect on sexually transmissible HIV. Young men and women aged 15-30 years from the 40 administrative clusters in the uMkhanyakude district who attend any integrated SRH/HIV service are eligible for enrolment.

    Study Aim: Offering a choice of long-acting PrEP, such as the two-monthly injectable cabotegravir, in addition to the community-based oral PrEP and SRH will overcome the adherence, retention, and disclosure challenges of oral PrEP and lead to a population-level effect on sexually transmissible HIV.

    Specific Objectives:

    1. To measure the effectiveness of the choice of oral and long-acting PrEP, including injectable (CAB LA) and vaginal ring (DapiRing), and post exposure prophylaxis (PEP) on increasing effective uptake (adoption), retention, and adherence of PrEP compared to oral PrEP in young people aged 15-30 in rural South Africa and to estimate the preliminary effect on transmissible HIV and HIV incidence.
    2. To understand real-world implementation:
      a. To explore the acceptability, preference, and reach of CAB-LA from the perspective of young people aged 15-30 and their communities in rural South Africa.
      b. To understand the feasibility, affordability, and scalability of delivering CAB-LA through community-based PrEP with SRH.
      c. To identify implementation challenges and practical solutions for CAB-LA initiation, laboratory monitoring (e.g. RNA testing), and safe stopping within nurse-led and rural community-based clinical settings.
      d. To evaluate the safety and tolerability of CAB-LA compared to oral PrEP.
    Kind of Data

    PrEP user's clinical data

    Unit of Analysis

    Sexual reproductive health and HIV-neutral service participants.

    Version

    Version Description

    v1.0.0

    Scope

    Topics
    Topic Vocabulary URI
    Adolescents; young adults; HIV infections/prevention & control; South Africa/epidemiology; sexual health; randomised controlled trials, PrEP; HIV prevention; clinical adherence; patient management. Africa Health Research Institute www.ahri.org
    Keywords
    STI, partner notification, HIV prevention, clinical management.

    Coverage

    Geographic Coverage

    Health and demographic surveillance site in the rural KwaZulu-Natal.

    Universe

    Long-acting HIV Pre-Exposure Prophylaxis integrated with community-based sexual and reproductive health in South Africa (LAPIS): A hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation. About 26,000 15-30 AYAs from 40 geographical areas (clusters) residing in the 40 clusters of the uMkhanyakude District in rural KwaZulu Natal are eligible to receive “LAPIS” intervention. Of these, ~20% are at risk of HIV acquisition and would benefit from PrEP and STI clinical management. The unit of randomisation is the administrative area supported by a pair of peer navigators: 40 administrative areas are randomised to receive the intervention.

    Producers and sponsors

    Primary investigators
    Name Affiliation
    Prof. Maryam Shahmanesh Africa Health Research Institute
    Dr. Limakatso Lebina Africa Health Research Institute
    Producers
    Name
    Africa Health Research Institute
    Funding Agency/Sponsor
    Name Abbreviation Role
    Bill and Melinda Gates Foundation BMG Funder
    Other Identifications/Acknowledgments
    Name Affiliation Role
    Jaco Dreyer Africa Health Research Institute Data management, cleaning, and analysis

    Sampling

    Sampling Procedure

    Clinical cohort: all young people aged 15-30 years who are residing in a trial cluster and attend one of the study clinics or public health clinics, following informed consent/assent. Baseline and endline surveys, n=3200, 16-30-year-old male and females randomly selected from the health and demographic surveillance survey area, following informed consent (aged 18 and above) and informed assent and parental/guardian informed consent (aged 16-17).

    For the surveys, aged 16-30, residing in the HDSS and able to provide informed consent (18+) or informed assent and parental consent (aged 16-17). For the clinical cohort, aged 15-30, residing in the trial clusters, attending one of the study clinics or public health clinics, and providing informed consent/assent to use their clinical data

    Data collection

    Dates of Data Collection
    Start End
    2024-05-01 2026-05-31

    Data processing

    Data Editing

    The data collected and captured on REDCap was uploaded to a MySQL database server within AHRI's secure server cluster.

    Data Access

    Access conditions

    Access to the data requires accurate completion of the online data access application form accessible on the AHRI Data repository(https://data.ahri.org/). Data users are required to abide by the data use conditions stipulated on the application for access to the data. Failure to do so may result in their data access privileges being revoked by the Data Custodian. In order to recognise the effort and intellectual contributions of AHRI investigators in producing and curating the data, users of AHRI data must acknowledge the source of the data and abide by the terms and conditions under which the data is accessed and must cite the dataset in publication using the citation provided as part of this documentation. All analytical datasets published on the AHRI Data Repository are assigned digital object identifier (DOIs) and the DOIs can be found on the Data Repository under Study Description tab - Access policy. AHRI data users are required to always cite the dataset using the relevant DOI.

    Citation requirements

    Shahmanesh, Prof Maryam, & Lebina, Dr. Limakatso. (2025). cRCT of Long-acting PrEP Integrated with Community-based Sexual Health (LAPIS) – Clinical Management [Data set]. Africa Health Research Institute.
    DOI:https://doi.org/10.23664/AHRI.LAPIS.ESource.Clinical.Management.2025

    Metadata production

    DDI Document ID

    AHRI.LAPIS.ESource.Clinical.Management.2025.v1

    Producers
    Name Abbreviation
    Africa Health Research Institute AHRI
    Back to Catalog
    AHRI Data Repository

    © AHRI Data Repository, All Rights Reserved.